Case Report
Published on 23 Apr 2024
Case report: Cerebrospinal fluid neutrophilic pleocytosis upon intrathecal triamcinolone injection
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1372266
Type at least 3 characters
1,032 articles
Articles
Review
Accepted on 22 Apr 2024
Stem Cell Therapies: A New Era in the Treatment of Multiple Sclerosis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1389697
Original Research
Published on 19 Apr 2024
Practical tool to identify Spasticity-Plus Syndrome amongst patients with multiple sclerosis. Algorithm development based on a conjoint analysis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1371644
- 198 views
Systematic Review
Published on 18 Apr 2024
Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1380654
- 356 views
Case Report
Published on 18 Apr 2024
Case report: Headache as the sole neurological symptom in autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1366263
- 262 views
Case Report
Published on 18 Apr 2024
Case report: A case of anti-glycine receptor encephalomyelitis triggered by post-transplant or COVID-19 infection?
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1356691
- 204 views
Brief Research Report
Accepted on 16 Apr 2024
IL-6 receptor antibody treatment improves muscle weakness in experimental autoimmune myasthenia gravis mouse model
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1356300
Case Report
Published on 16 Apr 2024
Case report: Transition from anti-CD20 therapy to inebilizumab for 14 cases of neuromyelitis optica spectrum disorder
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1352779
- 774 views
Original Research
Published on 16 Apr 2024
Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MS
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1388941
- 175 views
Original Research
Accepted on 15 Apr 2024
Patterns of Multiple Sclerosis Presentation to the Emergency Department
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1395822
Original Research
Accepted on 11 Apr 2024
"A second birthday"? Experiences of persons with multiple sclerosis treated with autologous hematopoietic stem cell transplantation - a qualitative interview study
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1384551
Original Research
Published on 10 Apr 2024
People with newly diagnosed multiple sclerosis benefit from a complex preventative intervention—a single group prospective study with follow up
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1373401
- 240 views
Systematic Review
Published on 10 Apr 2024
Risk of secondary immune thrombocytopenia following alemtuzumab treatment for multiple sclerosis: a systematic review and meta-analysis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1375615
- 206 views
Mini Review
Published on 09 Apr 2024
A rapid review of differences in cerebrospinal neurofilament light levels in clinical subtypes of progressive multiple sclerosis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1382468
- 262 views
Original Research
Published on 08 Apr 2024
Primary CNS vasculitis: insights into clinical, neuropathological, and neuroradiological characteristics
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1363985
- 232 views
Study Protocol
Published on 04 Apr 2024
Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in Italy
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1379712
- 423 views